Amarin (NASDAQ:AMRN) reported a significantly narrowed fourth-quarter loss on Wednesday, bolstered by a global restructuring plan that has repositioned the biopharmaceutical firm for a pivot toward sustainable profitability in 2026.
The Dublin-based company posted a net loss of $1.2 million for the quarter, a 97% improvement over the $48.6 million loss recorded in the prior-year period.
On an adjusted basis, which excludes restructuring charges and stock-based compensation, Amarin earned $0.01 per share.
Total revenue for the quarter was $49.2 million, down 21% from $62.3 million in Q4 2024.
This decline reflects the ongoing impact of generic competition in the U.S. market and the transition of its European business to a partnered model under Recordati S.p.A.
For the full year 2025, Amarin reported total revenue of $213.6 million and a net loss of $38.8 million, or $0.09 per share.
The narrowed annual loss follows the execution of a "Global Restructuring Plan" initiated in mid-2025, which has already realized approximately $31 million of its $70 million annual savings target.
A standout highlight of the report was the company’s return to positive cash flow during the quarter—a milestone management had previously not expected to reach until 2026.
Amarin ended the year with $303 million in cash and investments and remains entirely debt-free.